A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
暂无分享，去创建一个
L. Thal | M. Sano | D. Knopman | M. Rossor | M. Philpot | L. Harrell | M. Weiner | G. Schwartz | A. Goldberg | S. Bodenheimer | J. Schor | D. Knopman